Elocalcitol yields strong Ph IIb BPH findings

BioXell SpA says that Phase IIb trial data on elocalcitol in benign prostatic hyperplasia presented at the American Urological Association annual meeting, held in Orlando, Florida, show that the agent is effective in improving maximum urinary flow rate and ameliorating lower urinary tract symptoms.

The Italian drugmaker's lead product also arrested prostate growth and prevented the risk of acute urinary retention and need for surgery, all of which are key parameters of BPH progression. These characteristics, together with an exceptional and placebo-like safety profile, indicate elocalcitol's strong potential to become the monotherapy of choice for BPH treatment, the firm noted.

Lead investigator Francesco Montorsi stated that "the presentation of these results at one of the most renowned international urology conferences is an important step in gaining greater awareness among the urology community of a potential shift in treatment strategy for BPH. Judging from the many one-on-one discussions we have already had regarding elocalcitol with other experts in the field, we expect a lot of additional interest in these results."